Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$36.5m

Grace Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GRCE?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms641,0836.32%
Institutions746,9627.37%
Hedge Funds959,5719.46%
Private Companies1,056,08710.4%
Individual Insiders2,836,71528%
General Public3,899,44338.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.

Top Shareholders

Top 23 shareholders own 61.54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.9%
Vimal Kavuru
1,614,399US$5.8m0%no data
9.46%
ADAR1 Capital Management, LLC
959,571US$3.5m0%0.64%
9.19%
SS Pharma LLC
931,743US$3.4m0%no data
7.71%
Iyer Sambamurty
781,592US$2.8m0%no data
6.32%
Aigh Capital Management, LLC
641,083US$2.3m0%1.0%
4.88%
Bank of America Corporation, Asset Management Arm
494,698US$1.8m0%no data
3.65%
S. Kottayil
370,354US$1.3m0%no data
2.22%
The Vanguard Group, Inc.
225,000US$810.0k0%no data
1.23%
Kottayil Grace Pharma LLC
124,344US$447.6k0%no data
0.37%
Edward Neugeboren
37,895US$136.4k0%no data
0.21%
Prashant Kohli
21,357US$76.9k0%no data
0.16%
Renaissance Technologies LLC
16,147US$58.1k0%no data
0.11%
Amresh Kumar
11,118US$40.0k0%no data
0.03%
Geode Capital Management, LLC
3,058US$11.0k-0.65%no data
0.027%
Tower Research Capital Europe Limited
2,732US$9.8k0%no data
0.027%
National Bank Investments Inc.
2,719US$9.8k-6.27%no data
0.019%
Morgan Stanley, Investment Banking and Brokerage Investments
1,882US$6.8k0%no data
0.0054%
RBC Dominion Securities Inc., Asset Management Arm
543US$2.0k-7.02%no data
0.001%
Activest Wealth Management, LLC
104US$376.00%no data
0.00028%
UBS Asset Management AG
28US$102.2-99.6%no data
0.00028%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
28US$102.20%no data
0.00017%
JPMorgan Chase & Co, Brokerage and Securities Investments
17US$62.10%no data
0.00006%
IFP Advisors, LLC
6US$21.90%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:04
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Grace Therapeutics, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeByron Capital Markets